JPS633845B2 - - Google Patents
Info
- Publication number
- JPS633845B2 JPS633845B2 JP4020179A JP4020179A JPS633845B2 JP S633845 B2 JPS633845 B2 JP S633845B2 JP 4020179 A JP4020179 A JP 4020179A JP 4020179 A JP4020179 A JP 4020179A JP S633845 B2 JPS633845 B2 JP S633845B2
- Authority
- JP
- Japan
- Prior art keywords
- cobalt
- thiamine
- agent
- chlorophyllin
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019157 thiamine Nutrition 0.000 claims description 6
- 229960003495 thiamine Drugs 0.000 claims description 6
- 239000011721 thiamine Substances 0.000 claims description 6
- 230000017531 blood circulation Effects 0.000 claims description 5
- 229940099898 chlorophyllin Drugs 0.000 claims description 4
- 235000019805 chlorophyllin Nutrition 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 241000700159 Rattus Species 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- WXASNDZTGYYQHX-UHFFFAOYSA-L 18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate;cobalt(2+);hydron Chemical compound [H+].[H+].[H+].[Co+2].C1=C([N-]2)C(CC)=C(C)C2=CC(C(=C2C)C=C)=NC2=CC(C(C2CCC([O-])=O)C)=NC2=C(CC([O-])=O)C2=NC1=C(C)C2=C([O-])[O-] WXASNDZTGYYQHX-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- -1 amine salts Chemical class 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000002467 anti-pepsin effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 108010012944 Tetragastrin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical class [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4020179A JPS55133315A (en) | 1979-04-02 | 1979-04-02 | Curing and preventive agent for digestive ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4020179A JPS55133315A (en) | 1979-04-02 | 1979-04-02 | Curing and preventive agent for digestive ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55133315A JPS55133315A (en) | 1980-10-17 |
| JPS633845B2 true JPS633845B2 (enrdf_load_stackoverflow) | 1988-01-26 |
Family
ID=12574162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4020179A Granted JPS55133315A (en) | 1979-04-02 | 1979-04-02 | Curing and preventive agent for digestive ulcer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55133315A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2764287B2 (ja) * | 1988-11-30 | 1998-06-11 | 株式会社ミドリ十字 | 胃炎治療剤 |
-
1979
- 1979-04-02 JP JP4020179A patent/JPS55133315A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55133315A (en) | 1980-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60208979A (ja) | シクロデキストリンとの複合化包接化合物、その製造方法および該化合物を含有する抗炎症、鎮痛および解熱効果を有する医薬組成物 | |
| JPS60252414A (ja) | 医薬組成物 | |
| RU2228331C2 (ru) | Нитратные соли гетероциклических соединений, способ их получения и фармацевтические композиции на их основе | |
| EP0154009B1 (en) | Use of a thiazide diuretic for the manufacture of a non-diuretic antihypertensive medicament | |
| WO1996012484A1 (en) | Antianemic agent containing iron and difructose | |
| KR940011244B1 (ko) | 신장 질환 치료제 | |
| JPS633845B2 (enrdf_load_stackoverflow) | ||
| JPS62207212A (ja) | 抗アレルギ−剤 | |
| WO1991017751A1 (en) | Orally administrable gallium compositions and methods of treatment therewith | |
| JPS604172A (ja) | カルノシン水酸化亜鉛塩およびその製造法 | |
| CN100497303C (zh) | 磺化去氢枞酸亚铁盐、制备方法及其医药用途 | |
| JP3024789B2 (ja) | 血圧降下剤 | |
| JPH0374329A (ja) | 胃炎治療剤 | |
| JPH0446124A (ja) | 抗潰瘍剤 | |
| JPH07504153A (ja) | ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物 | |
| JP2811136B2 (ja) | シメチジン亜鉛錯体 | |
| JPH11147822A (ja) | 消化性胃腸疾患の予防又は治療方法 | |
| JPS6337089B2 (enrdf_load_stackoverflow) | ||
| US4215143A (en) | Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient | |
| HK40064492B (en) | Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof | |
| JPS61145117A (ja) | 抗消化性潰瘍剤 | |
| JP3685508B2 (ja) | 抗ウレアーゼ剤 | |
| JPH0361654B2 (enrdf_load_stackoverflow) | ||
| AU2021260856A1 (en) | Systemic formulation of a pyridinone derivate for coeliac disease | |
| JPS6345222A (ja) | 腎不全の保存療法剤 |